-
Fulvestrant, sold
under the
brand name
Faslodex among others, is an
antiestrogenic medication used to
treat hormone receptor (HR)-positive metastatic...
-
factor receptor 2-negative
breast cancer when used in
combination with
fulvestrant. The US Food and Drug
Administration (FDA)
considers it to be a first-in-class...
- ZB716, also
known as
fulvestrant-3-boronic acid, is a synthetic, steroidal,
orally active antiestrogen which is
under development for the
treatment of...
-
palbociclib is
prescribed as a
combination therapy with
either letrozole or
fulvestrant.
Patients should also not
consume CYP3A
inhibitors or
inducers while...
-
October 2024.
Inavolisib is
indicated in
combination with
palbociclib and
fulvestrant for the
treatment of
adults with endocrine-resistant, PIK3CA-mutated...
-
alters a patient's hormones". In
studies that
compared fulvestrant plus
abemaciclib to
fulvestrant plus
placebo in
breast cancer patients, progression-free...
-
clinical trials: The
phase III
trial BELLE-2
compared buparlisib +
fulvestrant with
fulvestrant alone in
patients with
advanced or
metastatic HER2-negative,...
- used to
treat certain types of
breast cancer. It is used
together with
fulvestrant. It is
taken by mouth. It is
marketed by Novartis.
Common side effects...
-
tamoxifen is no
longer effective.
Fulvestrant is a SERD drug that acts by
damaging and
blocking estrogen receptors.
Fulvestrant is
currently only
approved by...
-
choice of
endocrine therapy. The
choices for the
control arm
included fulvestrant, or an
aromatase inhibitor.
Randomization was
stratified based on whether...
